Skip to Main content Skip to Navigation
Journal articles

Low-dose statin treatment increases prostate cancer aggressiveness

Abstract : Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.
Document type :
Journal articles
Complete list of metadata
Contributor : Ghislain Bidaut Connect in order to contact the contributor
Submitted on : Wednesday, May 29, 2019 - 2:49:13 PM
Last modification on : Wednesday, November 3, 2021 - 9:44:28 AM

Links full text




Alfredo Caro-Maldonado, Laura Camacho, Amaia Zabala-Letona, Veronica Torrano, Sonia Fernandez-Ruiz, et al.. Low-dose statin treatment increases prostate cancer aggressiveness. Oncotarget, Impact journals, 2018, 9 (2), pp.1494-1504. ⟨10.18632/oncotarget.22217⟩. ⟨hal-02143588⟩



Record views